Cited by 460Alzheimer's disease research and treatmentsTea Polyphenols and EffectsMedicinal Plants and Neuroprotection

Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice

Rezai-Zadeh, Kavon, Arendash, Gary W., Hou, Huayan, Fernandez, Frank, Jensen, Maren, Runfeldt, Melissa, Shytle, R. Douglas, Tan, Jun·2008·Brain Research

Abstract

We previously reported that intraperitoneal (i.p.) injection (20 mg/kg) of (-)-epigallocatechin-3-gallate (EGCG), the main polyphenolic constituent of green tea, decreased beta-amyloid (Abeta) levels and plaques via promotion of the non-amyloidogenic alpha-secretase proteolytic pathway in "Swedish" mutant amyloid precursor protein overexpressing (APPsw, Tg) mice. Here, we find that EGCG administered orally in drinking water (50 mg/kg) similarly reduces Abeta deposition in these mice. Following a six month treatment of an 8 month old cohort, immunohistochemical analysis of coronal sections reveals that plaque burdens were reduced in the cingulate cortex, hippocampus, and entorhinal cortex by 54%, 43%, and 51%, respectively. Congo red plaque burdens were decreased in the cingulate cortex, hippocampus, and entorhinal cortex by 53%, 53%, and 58%, respectively as well. ELISA of brain homogenates of the treatment Tg mice revealed consistent reductions in both Abeta1-40 and 1-42 soluble and insoluble forms. In the present study we also investigated the effect EGCG administration had on tau pathology and cognition in Tg mice. Both i.p. and orally-treated Tg animals were found to have modulated tau profiles, with markedly suppressed sarkosyl-soluble phosphorylated tau isoforms. Radial arm water maze (RAWM) testing for working memory indicated that EGCG provided cognitive benefit to Tg mice with both i.p. and oral administration, although i.p.-treated animals showed a more pronounced benefit because of the greater impairment of their Tg controls at the time of testing. Taken together, these data further the notion of EGCG dietary supplementation as a potentially safe and effective prophylaxis for Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1016/j.brainres.2008.02.107

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BACE performs proteolysis by generating soluble APPβ and CTFβ; CTFβ undergoes γ-secretase proteolysis to generate toxic Aβ neuropeptides with 40-43 amino acids, finally causing the amyloid plaques characteristic of Alzheimer's disease.

    “This protein known as the BACE performs proteolysis by generating a soluble fragment in the extracellular space known as “soluble APPβ” and an additional fragment bound to the plasma membrane, CTFβ peptide that undergoes proteolysis yet again by γ-secretase to generate toxic neuropeptides Aβ with 40–43 amino acids, finally causing the amyloid plaques characteristic of AD [165,166,167].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rezai-Zadeh, K., Arendash, G. W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., Shytle, R. D., & Tan, J.
Affiliations
  • University of South Florida (US)
  • USF Health Byrd Alzheimer's Institute (US)
Corresponding author
Tan, Jun
Venue
Brain Research
Publisher
Elsevier BV
Published
2008-06
Volume
1214
Pages
177-187
ISSN
0006-8993 (ISSN-L)
OpenAlex
W2052380265
Cited by
459
References
50
Citations by year
2026: 14 · 2025: 28 · 2024: 17 · 2023: 26 · 2022: 27 · 2021: 30 · 2020: 37 · 2019: 20 · 2018: 28 · 2017: 31 · 2016: 20 · 2015: 27 · 2014: 27 · 2013: 33 · 2012: 32
FWCI
13.81
Type
journal article
Language
en
Open access
closed
Locations
  • Brain Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (AG04418, P01AG004418, R21AG031037, P50AG025711, AG025711, AG031037)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Tea Polyphenols and Effects
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
epigallocatechin gallate, green tea polyphenols, Alzheimer's disease, amyloid plaques, tau phosphorylation, oral administration, working memory, cognitive impairment, dietary supplementation, neuroprotection
MeSH terms
Alzheimer Disease, Analysis of Variance, Animals, Catechin, Cognition Disorders, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Mice, Transgenic, Mutation, Phosphorylation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Neuroprotective Agents, Maze Learning, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review